Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Significant Increase in Short Interest

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 238,700 shares, a growth of 50.8% from the March 31st total of 158,300 shares. Based on an average daily volume of 215,100 shares, the […]

Related Keywords

,Vanguard Group Inc ,Corvus Pharmaceuticals ,Nasdaq ,Corvus Pharmaceuticals Inc ,Discovery Capital Management ,Renaissance Technologies ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals Price Performance ,Corvus Pharmaceuticals Company Profile ,Get Rating ,Capital Management ,Two Sigma Advisers ,Sigma Advisers ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Stocks ,Options ,Put ,Call ,